Around the world, pharmaceutical manufacturers and researchers’ objectives remain the same. To protect the safety of our community and to supply essential medicines for those who need them. This is our unique responsibility as an industry.
Sypharma is honoured to announce that we have collaborated with Vaxine Pty Ltd to manufacture a first in human vaccine and adjuvant against the CoVID 19 pandemic. Vaxine’s COVID19 vaccine using recombinant spike protein together with Advax-CpG55.2 adjuvant officially went into human trials yesterday – meeting their ambitious 30 June 2020 deadline set months ago.
“This is the 16th vaccine to enter trials globally but is the first COVID-19 vaccine developed in the Southern hemisphere to enter human trials, and the first COVID-19 vaccine designed with the help of AI,” said Professor Nikolai Petrovsky. With their lead product Advax delta inulin adjuvant technology for enhanced immunogenicity and protection, vaxine ate uniquely placed as a single stop for the fight against this pandemic. “We achieved great results with Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic, where we commenced clinical trials of a vaccine within 3 months of discovery of the virus. We hope to achieve similar results with their COVID-19 vaccine candidate when it is ready for human testing,” he says.
Sypharma has a long standing relationship with Vaxine with over a decade of manufacturing Advax delta inulin adjuvant; and are excited and are honoured to partner with this ground breaking work in bringing a CoVID-19 vaccine to market. Sypharma undertook the fill and finish of the CoVID-19 vaccine and the manufacture of the Advax delta inulin adjuvant products.
